Bronchial Asthma in Children Amidst the Novel Coronavirus Infection
Objective of the Review: to present current information on monitoring and therapy of bronchial asthma (BA) in children amidst the novel coronavirus infection COVID-19. Key Points. There is no evidence that controlled BA increases the risk of SARS-CoV-2 infection or leads to more severe COVID-19. Inhaled glucocorticosteroids (IGCS) to manage BA inhibit gene expression of major SARS-CoV-2 target receptors. Anti-inflammatory BA therapy, primarily IGCS, should not be discontinued until BA is controlled, thus mitigating the risk of unfavourable course of COVID-19. Nebuliser therapy at home remains the preferred treatment in pre-school children with BA. Conclusion. Amidst the novel coronavirus infection COVID-19, children with BA should receive individualised therapy depending on disease severity and rate of disease control. Keywords: bronchial asthma, children, novel coronavirus infection COVID-19.